Acknowledgement
REGN-COV2 (cocktail of two antibodies, casirivimab and imdevimab) was provided by Regeneron Pharmaceuticals, Inc. for the purpose of emergency compassionate use treatment
Ethical statement
First patient was not able to sign a written informed consent, his wife have accepted that his medical information’s was published. Two others patients signed a written informed consent.
The use of data was approved by Erasme University Hospital ethics committee
Author contributions
AP: Conceptualization, writing original draft, GV, NY, CM: Data curation, reviewing MH, DG, VDW, MC: reviewing, editing.
Disclosure statement
The authors declare no conflict of interest